Sugi Predict

Sugi Predict / Compounds / SCHEMBL182820

SCHEMBL182820

SCHEMBL182820

COc1c[c]ccc1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.49
▸ HTT P42858 2/20 0.49
▸ KDM4E B2RXH2 4/20 0.44
▸ HPGD P15428 4/20 0.44
▸ TDP1 Q9NUW8 3/20 0.44
▸ MAPT P10636 1/20 0.44
▸ LCK P06239 1/20 0.43
▸ FYN P06241 1/20 0.43
▸ CA12 O43570 3/20 0.42
▸ CA1 P00915 3/20 0.42
▸ CA2 P00918 3/20 0.42
▸ CA7 P43166 3/20 0.42
▸ CA9 Q16790 3/20 0.42
▸ CA14 Q9ULX7 3/20 0.42
▸ HSD17B10 Q99714 3/20 0.41
▸ CA4 P22748 2/20 0.40
▸ CA6 P23280 2/20 0.40
▸ MYC P01106 1/20 0.40
▸ TPMT P51580 1/20 0.40
▸ PPARG P37231 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7355446 0.86 HTT (0.46) ALDH1A1HTTKDM4EHPGDMAPT
SCHEMBL2188777 0.85 ALDH1A1 (0.44) ALDH1A1HTTKDM4EHPGDTDP1
SCHEMBL182690 0.83 MKNK1 (0.40) ALDH1A1HTTKDM4EHPGDTDP1
SCHEMBL182737 0.83 KDM4E (0.44) ALDH1A1HTTKDM4EHPGDMAPT
SCHEMBL4334104 0.80 TSHR (0.47) ALDH1A1HTTKDM4EHPGDTDP1
SCHEMBL182598 0.80 SMN1; SMN2 (0.35) ALDH1A1HPGDMAPTKMT2A
SCHEMBL4333771 0.80 ALDH1A1 (0.46) ALDH1A1HTTKDM4EHPGDTDP1
SCHEMBL182862 0.80 PLK1 (0.49) ALDH1A1HPGDMAPTHSD17B10TSHR
SCHEMBL9827992 0.78 TSHR (0.49) ALDH1A1TDP1MAPTCA12CA1
SCHEMBL28774205 0.76 HPGD (0.38) HTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110317328-A The preparation method of polyarylate of the one kind based on 2- (4- carboxyl -3- methoxyphenyl) -5- pyridone and imidazoles 浙江甬仑聚嘉新材料有限公司 2019-10-11 — — CN claimed
US-20190225611-A1 SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN X-RX, INC. 2019-07-25 — — US claimed
US-9682955-B2 Quinazoline derivatives useful as CB-1 inverse agonists JANSSEN PHARMACEUTICA NV (BE) 2017-06-20 — — US claimed
US-9682940-B2 Indazole derivatives useful as CB-1 inverse agonists JANSSEN PHARMACEUTICA NV (BE) 2017-06-20 — — US claimed
WO-2017034872-A1 INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-03-02 — — WO claimed
US-20170057925-A1 INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-03-02 — — US claimed
WO-2016040081-A1 QUINAZOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2016-03-17 — — WO claimed
US-20160068512-A1 Quinazoline Derivatives Useful as CB-1 Inverse Agonists JANSSEN PHARMACEUTICA NV (BE) 2016-03-10 — — US claimed
US-9249163-B2 PDE10a inhibitors for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV. (BE) 2016-02-02 — — US claimed
WO-2014200885-A1 PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2014-12-18 — — WO claimed
US-20140364414-A1 PDE 10a Inhibitors for the Treatment of Type II Diabetes JANSSEN PHARMACEUTICA, NV (BE) 2014-12-11 — — US claimed
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 — — EP claimed
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors NOVARTIS AG 2009-10-15 — — US claimed
EP-2049502-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2009-04-22 — — EP claimed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 — — WO claimed
US-20190225611-A1 SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN X-RX, INC. 2019-07-25 — — US disclosed
US-10233182-B2 Substituted spirocyclic inhibitors of autotaxin X-RX, INC. (US) 2019-03-19 — — US disclosed
EP-0391405-A2 Silver halide photographic material and method for processing thereof FUJI PHOTO FILM CO., LTD. (JP) 1990-10-10 — — EP disclosed
EP-0337490-A2 Silver halide light-sensitive photographic material Fuji Photo Film Co., Ltd. (JP) 1989-10-18 — — EP disclosed
US-3953604-A INHALATION, ANTI-ASTHMA MILES LABORATORIES, INC. (US) 1976-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10233182-B2 Substituted spirocyclic inhibitors of autotaxin ENPP2, CXCR3, SLC10A1 ALDH1A1 1900/4885HTT 1990/4885KDM4E 3789/4885
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors PDPK1, PI4KA, PIK3CA ALDH1A1 1849/4885HTT 4354/4885KDM4E 1674/4885
US-20140364414-A1 PDE 10a Inhibitors for the Treatment of Type II Diabetes PDE2A, PDE3B, PDE3A ALDH1A1 381/4885HTT 4707/4885KDM4E 1186/4885
US-20190225611-A1 SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN ENPP2, SLC10A1, CXCR3 ALDH1A1 1493/4885HTT 2095/4885KDM4E 3762/4885
US-20170057925-A1 INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS CNR1, GPR119, CNR2 ALDH1A1 689/4885HTT 2988/4885KDM4E 3703/4885
US-20160068512-A1 Quinazoline Derivatives Useful as CB-1 Inverse Agonists CNR1, CNR2, GPR119 ALDH1A1 1414/4885HTT 2370/4885KDM4E 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.